A novel class of NaV1.7 inhibitors has been identified by high-throughput screening followed by structure activity relationship studies. Among this series of compounds, piperidine 9o showed potent human and mouse NaV1.7 inhibitory activities with fair subtype selectivity over NaV1.5. Compound 9o successfully demonstrated analgesic efficacy in mice comparable to that of the currently used drug, mexiletine, but with an expanded central nervous system safety margin.
Keywords: CNS side effects; High-throughput screening; Pain; Piperidine; Voltage-gated sodium channel.
Copyright © 2015 Elsevier Ltd. All rights reserved.